- This is the first time the plasma industry has partnered with a government in a groundbreaking global public-private alliance to achieve plasma medicine self-sufficiency, a game-changing model that ...

Grifols S.A. has received certification from the European Medicines Agency (EMA) for the entire value chain of Grifols Egypt ...

Blood plasma is big business — especially along the U.S.–Mexico border. Every day, thousands of Mexican citizens cross ...

Revenue momentum remains strong and EBITDA execution is intact, but FX-adjusted guidance implies Q4 slightly below consensus ...

- The operation aligns with Grifols' commitment to helping countries reach self-sufficiency of life-sustaining plasma-derived medicines According to Víctor Grífols Deu, co-CEO of Grifols, "This deal ...

BARCELONA, Spain, April 18, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today officially ...

- The combination of Grifols and Talecris will create a diversified, global provider of life-saving and life enhancing plasma protein therapeutics built on the strong global presence of Grifols and ...

Plasma donation is a painless procedure that thousands of people do each day. It is a great way to take a break in the middle of the day while helping others! All donors receive a thorough health ...

Market share in the global plasma-derived protein business is concentrated among a small number of global players, and Grifols lifted itself to the level of competitors Takeda and CSL with the $3.7 ...

LONDON (Reuters) - Shares in Grifols fell as much as over 40% on Tuesday, wiping $3.83 billion off its market value, after hedge fund Gotham City Research questioned its accounting, prompting the ...

Plasma is the lifeblood of Grifols, serving as the raw material for the biological medicines that generate most of the company’s revenue. But the Barcelona-based firm has eyed expansion beyond ...